TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-09-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/298 |
id |
doaj-dbabb1d1d4c64ac292367850dedb136f |
---|---|
record_format |
Article |
spelling |
doaj-dbabb1d1d4c64ac292367850dedb136f2020-11-24T23:57:32ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-09-0131e2011038e201103810.4084/mjhid.2011.038190TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.Charicleia Kelaidi0Lionel AdesPierre Fenaux1Department of Hematology, G. Papanikolaou Hospital of Thessaloniki, Exochi 57010, Greece.Service d’Hématologie, Hôpital Avicenne - Université Paris 13Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.http://www.mjhid.org/index.php/mjhid/article/view/298Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Charicleia Kelaidi Lionel Ades Pierre Fenaux |
spellingShingle |
Charicleia Kelaidi Lionel Ades Pierre Fenaux TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. Mediterranean Journal of Hematology and Infectious Diseases Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis |
author_facet |
Charicleia Kelaidi Lionel Ades Pierre Fenaux |
author_sort |
Charicleia Kelaidi |
title |
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. |
title_short |
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. |
title_full |
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. |
title_fullStr |
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. |
title_full_unstemmed |
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS. |
title_sort |
treatment of acute promyelocytic leukemia with high white cell blood counts. |
publisher |
PAGEPress Publications |
series |
Mediterranean Journal of Hematology and Infectious Diseases |
issn |
2035-3006 |
publishDate |
2011-09-01 |
description |
Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients. |
topic |
Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis |
url |
http://www.mjhid.org/index.php/mjhid/article/view/298 |
work_keys_str_mv |
AT charicleiakelaidi treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts AT lionelades treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts AT pierrefenaux treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts |
_version_ |
1725453407969345536 |